Africa

Asia Pacific

Europe

Middle East

North America

Latin America / Caribbean

South America

test

AbbViePro Logo 2023
MENU
Log in
or
Register
Log in
or
Register

LUMIGAN® 

LUMIGAN® is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers):LUM2[G] 

Frame 448
3 column card_2
LUMIGAN® (bimatoprost ophthalmic solution 0.01%)   
img
img
Our therapy areas
Immunology
Oncology
Neurology
Virology
Our therapy areas
Immunology
Oncology
Neurology
Virology
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
This website is intended for Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

This website is intended for Italy Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Date of Preparation: December 2018  |   Approval code AT-ABBV-210058 Aug 21    |    Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.

Date of Preparation: December 2018 

Approval code AT-ABBV-210058 Aug 21

Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.